Total medical devices industry venture financing deals in Q2 2019 worth $1.96bn were announced in the US, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked an increase of 33.2% over the previous quarter and a rise of 21.3% when compared with the last four-quarter average of $1.62bn.
The US held a 70.9% share of the global medical devices industry venture financing deal value that totalled $2.77bn in Q2 2019.
In terms of deal activity, the US recorded 176 deals during Q2 2019, marking a rise of 4.8% over the previous quarter and a rise of 10% over the last four-quarter average.
The US medical devices industry venture financing deals in Q2 2019: Top deals
The top five medical devices industry venture financing deals accounted for 21.9% of the overall value during Q2 2019.
The combined value of the top five medical devices industry venture financing deals stood at $430m, against the overall value of $1.96bn recorded for the quarter. The top announced medical devices industry venture financing deal tracked by GlobalData in Q2 2019 was Biomatics Capital Partners, BlueCross BlueShield Venture Partners, Camden Partners Holdings, Casdin Capital, Cowin Venture Capital, Exact Sciences, Gamma3, Section 32, Invus Group and Third Rock Ventures’ $110m venture financing of Thrive Earlier Detection.
In second place was the $100m venture financing of Acutus Medical by 8VC, Advent Venture Partners, Deerfield ManagementLP, GE Ventures, Opaleye Management, Orbimed Advisors, Pura Vida Investments and Xeraya Capital Sdn and in third place was Ballast Point Ventures and EW Healthcare Partners’ $82m venture financing of Tissuetech.
The $73m venture financing of Omada Health by Andreessen Horowitz, Cigna Ventures, Civilization Ventures, Kaiser Permanente Ventures, Norwest Venture Partners XII, Providence Ventures, Sanofi Ventures, USVP ManagementLlc and Wellington ManagementLLP and Ally Bridge Group, ArrowMark Partners, Driehaus Capital Management and RTW Investments’ venture financing of Pulmonx for $65m held fourth and fifth positions, respectively.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.